Central Nervous System Treatment Market Report (2022 to 2030) - Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Biogen Inc., and Novartis AG

| Source: Growth Plus Reports Growth Plus Reports

Pune, Dec. 15, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global central nervous system treatment market is expected to clock US$ 191.01 billion by 2030 and to grow at a CAGR of 9.10% during the forecast period. The growing geriatric population, which is more susceptible to central nervous system diseases, and the growing prevalence of neurological disorders. This exclusive information is published by Growth Plus Reports in its report titled “Central Nervous System Treatment Market – Global Outlook & Forecast 2022-2030”

The central nervous system is the largest component of the nervous system (comprising the brainstem, spinal cord, and spinal column), and is primarily in charge of regulating bodily functions as well as other activities like awareness, movement, thinking, speaking, feeling, and tasting. The central nervous system treatment market is driven by the growing prevalence of neurological diseases such as neurovascular diseases, neurodegenerative diseases, mental disorders, etc.

Download PDF Brochure of Central Nervous System Treatment Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/central-nervous-system-treatment-market/8014

Growth Drivers

The increasing prevalence of neurological diseases such as Parkinson's disease, Alzheimer’s disease, and other mental health conditions is fueling the growth of the global central nervous system treatment market. Parkinson's disease is the most prevalent age-related neurodegenerative disorder, after Alzheimer's disease. According to the Parkinson's Foundation, nearly 1 million people in the United States are living with Parkinson's disease (PD) and this number is expected to rise to 1.2 million by 2030. Men are 1.5 times as likely as women to suffer Parkinson's disease.

The global central nervous system treatment market has been analyzed from four perspectives – Disease Type, Drug Class, Distribution Channel, and Region

Excerpts from ‘by Disease Type’

The global central nervous system treatment market based on disease type has been segmented into:

  • Neurovascular Diseases (Hemorrhagic Stroke, Ischemic Stroke, And Others)
  • Neurodegenerative Diseases (Degenerative Diseases, Alzheimer’s Disease, Parkinson’s Disease, And Others)
  • Mental Health
  • Cns Trauma
  • Others

Neurodegenerative diseases are currently dominating the global central nervous system treatment market owing to the rising prevalence of Alzheimer's disease, Parkinson's disease, and degenerative spine diseases, neurodegenerative diseases. In addition, the aging population and rising mental health issues brought on by changing lifestyles, anxiety, and depression are boosting the market for neurodegenerative disease treatment worldwide.

Excerpts From ‘by Drug Class’

The global central nervous system treatment market, based on the drug class has been segmented into:

  • Antidepressants
  • Analgesics
  • Anesthetics
  • Anticonvulsants & Antiseizures
  • Anti-Parkinsonian Agents
  • Anxiolytics & Sedatives
  • CNS Stimulants
  • Others

The antidepressants segment is dominating the global central nervous system treatment market due to their high efficacy and therapeutic potential, as well as the growing demand for immunomodulatory prescription medications for central nervous system diseases. Furthermore, a promising pipeline and increased research & development for antidepressant drugs are contributing to the growth of the global antidepressant central nervous system treatment segment.

Excerpts from ‘by Region Segmentation

The global central nervous system treatment market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The global central nervous system treatment market is dominated by North America, followed by Asia Pacific. The highest market share of North America is attributed to the high prevalence of neurological disorders like Parkinson's disease, Alzheimer's disease, etc. in the region and the increasing numbers of approved drugs. Additionally, favorable reimbursement policies, developed infrastructure, and technological advancement are contributing to the growth of the North America central nervous system treatment market. Asia Pacific is also anticipated to experience the highest growth during the forecast period owing to the increasing geriatric population and developing healthcare infrastructure and emerging pharma industry.

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global central nervous system treatment market are:

  • AstraZeneca plc
  • Biogen
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Shire plc
  • Sanofi SA
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.

Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/central-nervous-system-treatment-market/8014

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
    1. Neurovascular Diseases
      1. Hemorrhagic Stroke
      2. Ischemic Stroke
      3. Others
    2. Neurodegenerative Diseases
      1. Degenerative Diseases
      2. Alzheimer’s Diseases
      3. Parkinson’s Diseases
      4. Others
    3. Mental Health
      1. Mood Disorders
      2. Psychotic Disorders
      3. Anxiety Disorders
      4. Others
    4. CNS Trauma
    5. Others
  6. GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Antidepressants
    2. Analgesics
    3. Anesthetics
    4. Anticonvulsants & Antiseizures
    5. Anti-Parkinsonian Agents
    6. Anxiolytics & Sedatives
    7. CNS Stimulants
    8. Others
  7. GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRUBUTION CHANNEL
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • 'Business Profile' of Key Players

Directly Purchase Premium Copy of Central Nervous System Treatment Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=hGrKYAY4WEG7TtPUKlDsuK6g0vJrgC0FcWiaShJU&report_id=8014&license=Single&submit=

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

 

            








        

            

                

                    
Tags

                            
                                Central Nervous System
                            

                



        


    

        
Related Links

        
    



    

        

        
Contact Data